VIDAZA 100 MG
AZACITIDINE : 100 MG · DIN 02336707 · BRISTOL-MYERS SQUIBB CANADA
Health Canada status: MARKETED
What is VIDAZA?
VIDAZA 100 MG contains AZACITIDINE : 100 MG. It is listed in the Health Canada Drug Product Database under DIN 02336707, held by BRISTOL-MYERS SQUIBB CANADA, supplied as POWDER FOR SUSPENSION for SUBCUTANEOUS administration. Health Canada currently lists it as marketed, status dated 07-Feb-2025. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is VIDAZA used for?
Adults not eligible for HSCT with Intermediate-2 and High-risk Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) with 20-30% blasts and multi-lineage dysplasia.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02336707 |
|---|---|
| Brand name | VIDAZA |
| Generic / active ingredient | AZACITIDINE : 100 MG |
| Manufacturer | BRISTOL-MYERS SQUIBB CANADA |
| Strength | 100 MG |
| Dosage form | POWDER FOR SUSPENSION |
| Route of administration | SUBCUTANEOUS |
| Schedule | Prescription |
| ATC code | L01BC07 AZACITIDINE |
| AHFS class | 12:04.00 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 07-Feb-2025 |
| Original market date | 2010-04-07 00:00:00 |
How is it administered?
75 mg/m2 subcutaneously daily for 7 days, followed by 21 days rest (28-day cycle). Minimum 6 cycles recommended. Premedicate with anti-emetics.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Store at 15-30°C. Reconstituted suspension: use within 45 mins at room temp or 8 hours if refrigerated (2-8°C).
How is it supplied?
100 mg single-use vials packaged in cartons of 1 vial.
Contraindications
Hypersensitivity to azacitidine or any ingredient; advanced malignant hepatic tumors.
Warnings and precautions
Serious risks: Thrombocytopenia, renal failure, differentiation syndrome. Risk of tumor lysis syndrome and necrotizing fasciitis. Monitor blood counts and renal/liver function.
Is AZACITIDINE in shortage in Canada?
A Canadian shortage report is on file for this molecule: Resolved — reported by SANDOZ CANADA INCORPORATED, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code L01BC07 AZACITIDINE. 7 of 14 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| AZACITIDINE FOR INJECTION | 100 MG | POWDER FOR SUSPENSION | FRESENIUS KABI CANADA LTD | MARKETED | DIN 02505177 |
| AZACITIDINE FOR INJECTION | 100 MG | POWDER FOR SUSPENSION | SANDOZ CANADA INCORPORATED | MARKETED | DIN 02529599 |
| AZACITIDINE FOR INJECTION | 100 MG | POWDER FOR SUSPENSION | DR REDDY'S LABORATORIES LTD | MARKETED | DIN 02462826 |
| AZACITIDINE FOR INJECTION | 100 MG | POWDER FOR SUSPENSION | HIKMA CANADA LIMITED | MARKETED | DIN 02507668 |
| ONUREG | 200 MG | TABLET | BRISTOL-MYERS SQUIBB CANADA | MARKETED | DIN 02510197 |
| ONUREG | 300 MG | TABLET | BRISTOL-MYERS SQUIBB CANADA | MARKETED | DIN 02510200 |
| AZACITIDINE FOR INJECTION | 100 MG | POWDER FOR SUSPENSION | STERIMAX INC | APPROVED | DIN 02534029 |
| AZACITIDINE FOR INJECTION | 100 MG | POWDER FOR SUSPENSION | JAMP PHARMA CORPORATION | DORMANT | DIN 02501791 |
| AZACITIDINE FOR INJECTION | 150 MG | POWDER FOR SUSPENSION | DR REDDY'S LABORATORIES LTD | APPROVED | DIN 02558815 |
| AZACITIDINE FOR INJECTION | 150 MG | POWDER FOR SUSPENSION | STERIMAX INC | APPROVED | DIN 02534037 |
Who else supplies AZACITIDINE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. AZACITIDINE appears in 411 registered pack listings across 10 markets, published on 7 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.